Announcement • Jan 22
EBOS Group Limited to Report First Half, 2026 Results on Feb 25, 2026 EBOS Group Limited announced that they will report first half, 2026 results on Feb 25, 2026 Declared Dividend • Aug 29
Final dividend of NZ$0.64 announced Shareholders will receive a dividend of NZ$0.64. Ex-date: 4th September 2025 Payment date: 24th September 2025 Dividend yield will be 4.0%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not adequately covered by earnings (99% earnings payout ratio). However, it is covered by cash flows (81% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 9.7% to bring the payout ratio under control. EPS is expected to grow by 34% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. New Risk • Aug 28
New minor risk - Dividend sustainability The dividend is not well covered by earnings. Payout ratio: 99% Dividend yield: 3.7% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Aug 28
EBOS Group Limited (NZSE:EBO) completed the acquisition of Next Generation Pet Foods Pty Ltd. EBOS Group Limited (NZSE:EBO) acquired Next Generation Pet Foods Pty Ltd for AUD 43 million on July 1, 2025. A cash consideration of AUD 43 million will be paid by EBOS Group Limited. As part of consideration, AUD 43 million is paid towards common equity of Next Generation Pet Foods Pty Ltd. The deal was fully funded through existing debt facilities and cash on hand. The transaction is expected to be marginally EPS accretive in the first year.
EBOS Group Limited (NZSE:EBO) completed the acquisition of Next Generation Pet Foods Pty Ltd on July 1, 2025. Reported Earnings • Aug 27
Full year 2025 earnings released Full year 2025 results: Revenue: AU$12.3b (down 7.0% from FY 2024). Net income: AU$215.1m (down 21% from FY 2024). Profit margin: 1.8% (down from 2.1% in FY 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Australia. Announcement • Aug 15
EBOS Group Limited, Annual General Meeting, Oct 29, 2025 EBOS Group Limited, Annual General Meeting, Oct 29, 2025. Location: at the park hyatt hotel, 99 halsey street, auckland New Zealand Announcement • Jun 03
EBOS Group Limited to Report Fiscal Year 2025 Results on Aug 27, 2025 EBOS Group Limited announced that they will report fiscal year 2025 results on Aug 27, 2025 Announcement • May 12
EBOS Group Limited has completed a Follow-on Equity Offering in the amount of AUD 54.272 million. EBOS Group Limited has completed a Follow-on Equity Offering in the amount of AUD 54.272 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: AUD 33.92 Announcement • Apr 11
EBOS Group Limited has completed a Follow-on Equity Offering in the amount of NZD 217.220005 million. EBOS Group Limited has completed a Follow-on Equity Offering in the amount of NZD 217.220005 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,926,876
Price\Range: NZD 36.65
Discount Per Security: NZD 0.69635
Transaction Features: Regulation S; Subsequent Direct Listing Announcement • Jan 31
EBOS Group Limited Announces Appointment of Coline Mcconville as A Director, Effective 1 February 2025 EBOS Group Limited announced the appointment of Coline Mcconville as A Director, Effective 1 February 2025. Announcement • Jan 22
EBOS Group Limited Appoints Grant Viney as Chief Executive Officer of EBOS Animal Care , Effective 1 February 2025 EBOS Group Limited announced the appointment of Mr. Grant Viney to the role of Chief Executive Officer of EBOS Animal Care with effect from 1 February 2025. Mr. Viney is currently the Executive General Manager of EBOS-owned Masterpet, having joined the business in 2019. The business, which includes premium natural pet food brand, Black Hawk, and the Vitapet food and treats range, has experienced strong and consistent growth under Mr. Viney's management. Before joining EBOS, Mr. Viney held senior roles at leading FMCG companies including Accolade Wines, PZ Cussons, Dairy Farmers Australia and Mars Confectionary. Announcement • Jan 14
EBOS Group Limited to Report First Half, 2025 Results on Jan 19, 2025 EBOS Group Limited announced that they will report first half, 2025 results on Jan 19, 2025 Announcement • Jan 03
EBOS Group Limited Appoints Matthew Muscio as Director EBOS Group Limited announced the appointment of Matthew Muscio as director. Date of appointment is 1 January 2025. Declared Dividend • Aug 23
Final dividend of NZ$0.64 announced Shareholders will receive a dividend of NZ$0.64. Ex-date: 29th August 2024 Payment date: 18th September 2024 Dividend yield will be 3.6%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (78% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Aug 23
EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024 EBOS Group Limited announced final dividend of NZD 0.61500000 per share. Dividend Payment Date is 18 September 2024. Record Date is 30 August 2024. Ex-Date is 29 August 2024. Reported Earnings • Aug 21
Full year 2024 earnings released: EPS: AU$1.41 (vs AU$1.33 in FY 2023) Full year 2024 results: EPS: AU$1.41 (up from AU$1.33 in FY 2023). Revenue: AU$13.2b (up 7.8% from FY 2023). Net income: AU$271.5m (up 7.2% from FY 2023). Profit margin: 2.1% (in line with FY 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.1% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Apr 27
EBOS Group Limited Announces Chief Financial Officer Changes EBOS Group Limited announced the appointment of Alistair Gray to the role of Chief Financial Officer (CFO) with effect from 30 September 2024. Mr. Gray is currently Deputy CFO at Endeavour Group. Mr. Gray joined Endeavour Group in 2018 just prior to the demerger from Woolworths and is responsible for the Group finance teams. Prior to Endeavour he held senior roles at Toll Group, Mondelez International and Coles and throughout his career has accumulated a wealth of consumer, retail and supply chain experience across Australia, New Zealand, the UK and Asia. Mr. Gray will be based at company’ Melbourne office. In announcing Mr. Gray’s appointment, the company also announced that its current CFO, Leonard Hansen, will move from the CFO role and continue with the company in the capacity of Chief Risk Officer (CRO). Leonard Hansen will continue in the role of the company’s CFO until Mr. Gray’s commencement in September. Recent Insider Transactions • Mar 08
Insider recently sold AU$4.9m worth of stock On the 1st of March, Matthew Muscio sold around 144k shares on-market at roughly AU$34.27 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Declared Dividend • Feb 23
First half dividend of NZ$0.60 announced Shareholders will receive a dividend of NZ$0.60. Ex-date: 29th February 2024 Payment date: 22nd March 2024 Dividend yield will be 3.4%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (78% earnings payout ratio) but not adequately covered by cash flows (98% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 22
First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023) First half 2024 results: EPS: AU$0.71 (up from AU$0.70 in 1H 2023). Revenue: AU$6.58b (up 7.1% from 1H 2023). Net income: AU$136.2m (up 3.0% from 1H 2023). Profit margin: 2.1% (in line with 1H 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.3% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year. Buy Or Sell Opportunity • Feb 02
Now 20% undervalued Over the last 90 days, the stock has risen 1.6% to AU$34.51. The fair value is estimated to be AU$43.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to decline by 0.5% per annum. Earnings are forecast to grow by 5.7% per annum over the same time period. Announcement • Jan 10
EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024 EBOS Group Limited announced that they will report first half, 2024 results on Feb 21, 2024 Announcement • Dec 20
EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million. EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million on December 19, 2023. The purchase price was funded from existing debt facilities and the transaction is expected to be immediately marginally EPS accretive.
EBOS Group Limited (NZSE:EBO) completed the acquisition of additional 39% stake in Transmedic Pte Ltd. from TS Lee on December 19, 2023. Announcement • Dec 15
Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk Paragon Care Limited (ASX:PGC) is understood to have hired Rothschild & Co as a defence adviser amid chatter in the market it has been in the cross hairs of EBOS Group Limited (NZSE:EBO). There's talk in the market that Paragon has bidders interested in the business at 40c a share. Paragon Care shares closed up 2.3% to 22c on 13 December 2023. Earlier, Paragon had said that it had not received approaches from EBOS, while both groups declined to comment on 13 December 2023. Its market value is $147 million. As earlier reported by DataRoom, EBOS held talks about a backdoor listing involving Chemist Warehouse, but instead, the pharmacy giant embarked on the $8 billion-plus move through EBOS's rival Sigma Healthcare. Buying Opportunity • Dec 12
Now 23% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be AU$43.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to decline by 0.8% per annum. Earnings is forecast to grow by 5.6% per annum over the same time period. Announcement • Dec 07
EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit EBOS Group Limited (NZSE:EBO) seems to be moving on quickly from its $4 billion courtship of Greencross Limited, with talk that it is eyeing Paragon Care Limited (ASX:PGC). While small, with just a $113.5 million market value, Paragon Care operates in the areas of specialty diagnostics and devices under brands such as Designs for Vision, Electro Medical Group, Specialist Medical Supplies and Immulab. Apparently, there's a large Asian private equity firm also interested in buying the business right now. However, should there be interest in Paragon it is likely to be early days, with sources close to the company saying it has not received approaches. Sources say the group has been yet to prove to the market it can deliver on its mergers and acquisition strategy. Other parties that have looked at Paragon in the past are Navis Capital, which now owns Device Technologies. Announcement • Nov 24
EBOS Not to Proceed with Acquisition in Animal Care Segment New Zealand EBOS Group Limited (NZSE:EBO) will not proceed with the potential transaction related to its animal care segment, the healthcare products distributor said on November 22, 2023. The announcement comes after local media reported the company would acquire TPG Capital-backed pets and vets business Greencross Limited. Buying Opportunity • Nov 08
Now 21% undervalued Over the last 90 days, the stock is up 3.7%. The fair value is estimated to be AU$43.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to decline by 0.8% per annum. Earnings is forecast to grow by 5.5% per annum over the same time period. Announcement • Sep 27
EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023 EBOS Group Limited announced Fully Franked Ordinary dividend for the six months ended June 30, 2023 of NZD 0.59514706 with Record Date 8 September, 2023; Ex Date 7 September, 2023 and Payment Date to be 29 September, 2023. Buying Opportunity • Sep 05
Now 21% undervalued Over the last 90 days, the stock is up 5.4%. The fair value is estimated to be AU$43.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.8%. For the next 3 years, revenue is forecast to decline by 0.8% per annum. Earnings is forecast to grow by 5.3% per annum over the same time period. Upcoming Dividend • Aug 31
Upcoming dividend of NZ$0.60 per share at 3.0% yield Eligible shareholders must have bought the stock before 07 September 2023. Payment date: 29 September 2023. Payout ratio is on the higher end at 76%, however this is supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (2.6%). Reported Earnings • Aug 23
Full year 2023 earnings released: EPS: AU$1.33 (vs AU$1.15 in FY 2022) Full year 2023 results: EPS: AU$1.33 (up from AU$1.15 in FY 2022). Revenue: AU$12.2b (up 14% from FY 2022). Net income: AU$253.4m (up 25% from FY 2022). Profit margin: 2.1% (up from 1.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Australia are expected to grow by 5.9%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to AU$32.33, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Healthcare industry in Australia. Total returns to shareholders of 69% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at AU$39.69 per share. Buying Opportunity • Jun 06
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be AU$44.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 4.6% per annum. Earnings is also forecast to grow by 11% per annum over the same time period. Reported Earnings • Feb 22
First half 2023 earnings released: EPS: AU$0.70 (vs AU$0.61 in 1H 2022) First half 2023 results: EPS: AU$0.70 (up from AU$0.61 in 1H 2022). Revenue: AU$6.15b (up 17% from 1H 2022). Net income: AU$132.2m (up 30% from 1H 2022). Profit margin: 2.2% (up from 1.9% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Australia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Sep 01
Upcoming dividend of NZ$0.51 per share Eligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio and cash payout ratio are on the higher end at 77% and 97% respectively. Trailing yield: 2.6%. Lower than top quartile of Australian dividend payers (6.6%). In line with average of industry peers (2.5%). Reported Earnings • Aug 25
Full year 2022 earnings released: EPS: AU$1.15 (vs AU$1.13 in FY 2021) Full year 2022 results: EPS: AU$1.15 (up from AU$1.13 in FY 2021). Revenue: AU$10.7b (up 17% from FY 2021). Net income: AU$202.6m (up 9.3% from FY 2021). Profit margin: 1.9% (down from 2.0% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.8% while the Healthcare industry in Australia is not expected to grow. Upcoming Dividend • Feb 24
Upcoming dividend of NZ$0.49 per share Eligible shareholders must have bought the stock before 03 March 2022. Payment date: 18 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Australian dividend payers (5.4%). Lower than average of industry peers (2.6%). Reported Earnings • Feb 19
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: EPS: AU$0.61 (up from AU$0.57 in 1H 2021). Revenue: AU$5.25b (up 13% from 1H 2021). Net income: AU$101.9m (up 9.7% from 1H 2021). Profit margin: 1.9% (down from 2.0% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 7.7%, compared to a 10% growth forecast for the industry in Australia. Recent Insider Transactions • Dec 19
Independent Director recently bought AU$55k worth of stock On the 13th of December, Tracey Batten bought around 2k shares on-market at roughly AU$36.50 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Upcoming Dividend • Sep 02
Upcoming dividend of NZ$0.48 per share Eligible shareholders must have bought the stock before 09 September 2021. Payment date: 24 September 2021. Trailing yield: 2.4%. Lower than top quartile of Australian dividend payers (5.2%). In line with average of industry peers (2.5%). Reported Earnings • Aug 23
Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$9.20b (up 5.0% from FY 2020). Net income: AU$185.3m (up 14% from FY 2020). Profit margin: 2.0% (up from 1.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Feb 25
Upcoming Dividend of NZ$0.44 Per Share Will be paid on the 18th of March to those who are registered shareholders by the 4th of March. The trailing yield of 3.0% is below the top quartile of Australian dividend payers (5.2%), but it is higher than industry peers (2.6%). Analyst Estimate Surprise Post Earnings • Feb 19
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 4.7%, compared to a 15% growth forecast for the Healthcare industry in Australia. Reported Earnings • Feb 18
First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$4.65b (up 6.3% from 1H 2020). Net income: AU$92.9m (up 14% from 1H 2020). Profit margin: 2.0% (up from 1.9% in 1H 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 11
New 90-day high: AU$28.30 The company is up 19% from its price of AU$23.87 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$28.77 per share. Is New 90 Day High Low • Jan 04
New 90-day high: AU$28.29 The company is up 25% from its price of AU$22.57 on 07 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$30.45 per share. Is New 90 Day High Low • Dec 17
New 90-day high: AU$25.38 The company is up 12% from its price of AU$22.70 on 18 September 2020. The Australian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$29.16 per share. Is New 90 Day High Low • Oct 13
New 90-day high: AU$23.21 The company is up 12% from its price of AU$20.78 on 15 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$25.10 per share. 
